European Commission Consults Public On Proposal To Revise Cosmetics Regulation

The Commission specifically cites “lack of specific provisions for endocrine disruptors, the applicability of a generic approach on risk management (GRA) for other harmful substances, the potential diverging opinions from committees responsible for the assessment of chemicals, and the lack of coherence between legislations on the definition of nanomaterials” as points of interest.